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Background: The difficulty of implementing guidelines for long-term oxygen therapy (LTOT)
has been recognized. We performed this analysis to evaluate the impact of a national quality
assurance register on the quality of LTOT and to suggest indicators with levels for excellent
quality LTOT.
Methods: Based on national register data on Swedish LTOT patients in 1987e2005, we
measured nine quality indicators and the achievement levels of the participating counties in
fulfilling these treatment criteria.
Results: There were improvements in the following eight quality indicators: access to LTOT,
PaO2 7.3 kPa without oxygen, no current smoking, low number of thoracic deformity patients
without concomitant home mechanical ventilation, >16 h of oxygen/day, mobile oxygen
equipment, reassessment of hypoxemia when LTOT was not started in a stable state of chronic
obstructive pulmonary disease (COPD) and avoidance of continuous oral glucocorticosteroids in
COPD. There was decline in the quality indicator PaO2> 8 kPa on oxygen. After improvements,
three criteria were fulfilled by 80% of the counties in 2004e2005.
Conclusions: We found improvements in eight of nine quality indicators. We suggest these indi-
cators with levels for excellent quality for use in quality assurance of LTOT based on our
results.
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Long-term oxygen therapy (LTOT) doubles survival time in
chronic obstructive pulmonary disease (COPD) complicated
by severehypoxemia (PaO2 7.3 kPa)1,2 but not bymoderate
hypoxemia (PaO2 7.4e8.7 kPa).
3,4 These findings led to.
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Chest Medicine in 1985, revised in 1993, and the American
Thoracic Society together with the European Respiratory
Society, among many others.5,6 It is recognized that it is
difficult to implement guidelines for the management of
LTOT.7 Adherence to the LTOT guidelines varies in different
countries and different parts of these countries.8e12
No beneficial effects of LTOT on survival time have been
demonstrated in conditions other than COPD causing respi-
ratory failure. One unpublished, randomised, controlled
trial showed no effects on survival with interstitial lung
disease.13 LTOT is, however, assumed to have beneficial
effects, such as the alleviation of dyspnoea and a reduction
in the negative effects of hypoxemia on the internal organs.
Consequently, there are recommendations for LTOT in idio-
pathic pulmonary fibrosis and pulmonary arterial
hypertension.5,14,15
The overall benefits of LTOT vary with access,5 the
appropriate selection of patients with regard to levels of
chronic hypoxemia,3,6,16,17 smoking avoidance8,18e20 and
provision of home mechanical ventilation (HMV) to patients
with thoracic deformity.21e23 Furthermore, the indication
for LTOT should be re-evaluated if the therapy is started
during an exacerbation of COPD.6,16,17
The benefits of LTOT also depend on performance in
terms of reaching the recommended oxygenation during
oxygen therapy,1,2 length of oxygen therapy per day1,2,8 and
access to mobile oxygen equipment when needed.1,24,25 It
can be assumed that avoidance of long-term oral gluco-
corticosteroids in COPD supports the treatment goals in
patients receiving LTOT.26e28
To facilitate the implementation of guidelines,
a national register provides a basis for evaluation and
subsequent improvements.8
The purpose of this evaluation was to investigate the
feasibility and the possible impact of a national quality
assessment register as a benchmarking tool for improved
LTOT and to suggest levels of excellent quality for indica-
tors based on such impact at national and regional levels.
Methods
Oxygen Register
The national register of patients undergoing LTOT in Swe-
den was started on 1 January 1987, with registration of
patients already receiving LTOT for chronic respiratory
failure and prospective registration of new patients starting
LTOT.5 The LTOT was based on guidelines from the Swedish
Society of Chest Medicine, agreed on in 1985 and subse-
quently revised in 1993. In November 2004, the register was
merged with the register of home mechanical ventilation to
create the Swedevox national quality assurance register, an
Internet-based register with on-line presentations of the
quality assessment results for the individual participating
centres, compared with national results.23
All adults receiving LTOT for chronic hypoxemia were
eligible for registration and were followed prospectively for
a minimum of one year. The coverage of the register was
assessed by repeated questionnaires to the participating
responsible respiratory physicians, and was found to beapproximately 85%. Patients receiving LTOT for short
periods as part of palliative treatment for lung cancer,
whether primary or secondary, were not included.
The register is intended to contribute to gradual
improvements in LTOT by annual distribution of the results.
The effective units in this process are the counties with
their responsible physicians.5 These physicians are the
contact persons for the Oxygen Register. They are respon-
sible for the organisation of LTOT in their counties and
reporting to the Oxygen Register. In each unit, specially
trained nurses participate in the treatment. These nurses,
or technicians at a few units, perform home visits to LTOT
patients. In 1987, there were oxygen nurses in some
counties and, by approximately 10 years later there were
oxygen nurses in all counties. Sweden was divided into 24
counties in 1987. In 2005, the division was changed to 20
counties; this division has been used in our calculations over
the entire observation period. The populations of the
counties varied between 1,606,157 and 133,389 in 1987 and
between 1,889,945 and 127,028 in 2005. There were
university hospitals in six of the counties. The number of
hospitals in each county varied between one and 10. There
was a pulmonary division or pulmonary outpatient depart-
ment at 96% of the hospitals. The overwhelming majority of
the LTOTs was prescribed by physicians with special training
in COPD and respiratory failure, either pulmonologists or
internists.
The quality indicators and their levels were discussed in
annual national reports and at meetings of the register,
with the participation of physicians and nurses involved in
LTOT, as well as continuously via mail and e-mail.LTOT indications and performance
According to the guidelines from the Swedish Society of
Chest Medicine, LTOT was indicated for patients with
 chronic hypoxemia due to COPD or other diseases,
 a stable disease course on optimum medical therapy for
at least three weeks,
 arterial oxygen tension (PaO2) when still breathing
room air of less than 7.0e7.5 kPa (7.3 kPa after 1993)
or signs of cor pulmonale or haematocrit >50% plus
room air PaO2 of around 7.5 kPa (7.4e8 kPa after 1993).
Arterial blood gas samples were taken at rest after
breathing air or the prescribed flow of oxygen for
a minimum of 20 min. The prescribed flow of oxygen was
defined using pulse oximetry in patients without hyper-
capnia and with repeated adjustment and arterial blood gas
samples in hypercapnic patients.
Smoking habits were checked by questions to the patients
and their relatives and caregivers. From 2002 and onwards,
the register stated whether or not LTOTwas initiated during
an exacerbation of COPD. An exacerbation was defined as a
deterioration of COPD serious enough to require hospitali-
zation and associated with respiratory failure.
Every regional ethics committee in Sweden, the National
Board of Health and Welfare, and the Data Inspection Board
approved the evaluation. All of the patients gave their
informed consent prior to inclusion.
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Patient selection criteria
From 1987 onwards:
 access to LTOT as the number of LTOT patients per
100,000 inhabitants,
 percentage of patients with PaO2 7.3 kPa when
breathing air, daytime at rest,
 percentage of patients who are not current smokers.
From 1993 onwards:
 a small number of patients with thoracic deformity
without concomitant HMV.
Performance of LTOT
From 1987 onwards:
 percentage of patients with PaO2> 8 kPa when
breathing oxygen,
 percentage of patients with prescribed dosage of
oxygen >16 h per day.
From 1989e2004:
 percentage of patients with access to mobile oxygen
equipment, registered at follow-up after one year.
From 2002 onwards:
 percentage of COPD patients with reassessment of
hypoxemia when breathing air if LTOT was not started
in a stable state, registered at follow-up after one year.
Concomitant treatment
From 1987e1989 and from 1995 onwards:
 percentage of COPD patients without continuous oral
glucocorticosteroids.
Data analyses
Data from the questionnaires were compared with data in
the Swedish Causes of Death Register kept by the Swedish
National Board of Health and Welfare. Both registers use
the Swedish census registration numbers, which secures
follow up on vital status for all Swedish citizens. In COPD
patients starting LTOT between 1987 and 2004, we
measured the crude survival rate during LTOT. We also
analysed the change in age and sex-adjusted first year and
overall survival rates according to the year of starting LTOT
in COPD patients starting LTOT between 1987 and 2004.
Use of quality indicators
As basic criteria, evidence from the literature was
used.1e3,6,8,15,16,18e22,24e29 Early experience from the
register, identifying major differences in access between
counties as a serious shortcoming, led to development of an
access criterion.5 Our early results showing impairedsurvival in current smokers and poor compliance with the
prescribed hours of oxygen in patients with a good perfor-
mance status also encouraged us to two criteria.8 For each
quality indicator, the counties level of achievement was
given for comparison with the national level achieved by all
participating centres. With the individual levels obtained by
these centres as guidance, a recommended level of
achievement was chosen as a marker of excellent quality,
e.g., XX% of patients have PaO2> 8 kPa when breathing
oxygen (Table 1).
Statistical analyses
Each quality indicator was analysed by comparing data from
1987 and 2005, or at some other start and end year, as
specified in the text. Statistical analyses of survival rates
were performed using KaplaneMeier and Cox’s regression
analysis. The calculations were made with the STATA 9
statistics package.
Results
Patients
Data on start of LTOT
During the period 1987e2005, 12,070 patients (49% male),
8379 (69%) of whom had COPD were registered when they
started LTOT (Fig. 1). The mean age of COPD patients when
starting LTOT increased from 66 to 74 years over the period
1987e2005. In 2005, 18% of the LTOT for COPD patients was
initiated during an exacerbation. In COPD, the mean values
of PaO2 and PaCO2 when breathing air were 6.6 0.9 and
6.3 1.2, respectively, and PaCO2 was above 6.0 kPa in 58%
of the COPD patients.
Survival in COPD
First year survival rate was 0.74 (95% confidence interval
0.73e0.75). There was no significant change in first year
survival rate according to starting year of LTOT.
Second year survival rate was 0.54 (95% confidence
interval 0.53e0.55) and five-year survival was 0.20 (95%
confidence interval 0.19e0.21%). In COPD patients, overall
survival was stable in LTOT from 1987 to 2004 after account
was taken of age and sex.
Quality indicators at national level
Table 1 shows the figures at national level at the start and
end of the observation period in the nine quality indicators,
divided into three categories. There were improvements in
eight quality indicators. The achievement of adequate
oxygenation (PaO2> 8 kPa) when breathing oxygen has
declined.
Access to therapy increased in terms of the number of
patients on LTOT. The prevalences in the separate counties
varied between 1.3 and 19.6 per 100,000 on 1 January 1987
and between 21.0 and 76.0 per 100,000 on 31 December
2005 (variations by a factor of 15 and 3.6, respectively) (not
shown in the Table 1). At national level, the prevalence of
Table 1 Quality indicators, proposed levels for excellent quality, and achieved performance level for the first and last year
cohort, respectively.
Quality indicator Proposed excellent
quality level
Achieved performance level first year
cohort and last year cohort
Year Level
Patient selection criteria
1. Access to LTOT (patients/100,000 inhabitants) >30 1987 7
2005 31
2. PaO2 7.3 kPa (% of patients) >85 1987 76
2005 85
3. Non-smokers (% of patients) 95 1987 96
2005 99
4. LTOT patients with thoracic wall
deformity without HMV (n)
None 1993 30
2005 5
Performance of LTOT
5. PaO2> 8 kPa on oxygen (% of patients) >90 1987 86
2005 80
6. More than 16 h a day (% of patients) >95 1987 91
2005 97
7. Mobile oxygen equipment (% of patients) >50 1989 48
2004 65
8. Reassessment of LTOT 1e3 months after initiation
during a COPD exacerbation (% of patients)
>95 2002 0
2005 30
Concomitant treatment
9. Avoidance of continuous oral glucocorticosteroids in
COPD (% of patients)
80 1987 54
2005 81
LTOT: long-term oxygen therapy; PaO2: arterial oxygen tension; HMV: home mechanical ventilation; and COPD: chronic obstructive
pulmonary disease.
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December 2005. The dominant underlying diseases were
COPD and pulmonary fibrosis (Fig. 1).
County quality achievement
At the end of the evaluation period, all counties had ach-
ieved our proposed quality level for the prescription of
oxygen for more than 16 h a day. Ninety per cent achievedFigure 1 Number of new patients (n) with long-term oxygen
therapy in 1987e2005 divided into causes of hypoxemia. A:
chronic obstructive pulmonary disease; :: pulmonary fibrosis;
-: thoracic cage deformity; C: other diseases.this level in terms of LTOT to non-smokers and 80% in terms
of providing the patients with mobile equipment (Table 2).
Conversely, only 25% of the counties managed to achieve
the quality levels for the reassessment of LTOT 1e3 months
after initiation during a COPD exacerbation, and only 25% of
the counties achieved the proposed quality level for
PaO2> 8 kPa on oxygen, a decline in achievement in
comparison with 2002 and 1987, respectively.
Discussion
We found considerable improvements in most quality indi-
cators after the initiation of the register in 1987, suggesting
that the register does function as a benchmarking tool for
quality assurance. There was substantial improvement in
access to LTOT and the adherence to treatment criteria in
terms of an increasing percentage of patients with severe
hypoxemia and a decreasing percentage of current
smokers. In spite of this, at national level, two of the nine
quality indicators were poorly fulfilled even in 2005,
including the percentage of patients reaching adequate
oxygenation when breathing oxygen, which actually
diminished during our observation period.
The annual reports and meetings for the personnel
responsible for LTOT focused on access, patient selection
and concomitant treatment. Likewise, attention has been
focused on appropriate equipment selection, including
lightweight mobile equipment, and reassessments of
hypoxemia. In this area, we observed improvements,
Table 2 Achievement among the counties (%) of excellent quality levels by quality indicator, first and last year of use of
indicator.
Proposed excellent quality level Counties achieving excellent quality
level first and last year of use of indicator
Year %
Patient selection criteria
1. Greater than 30 patients/100,000 inhabitants with access to LTOT 1987 0
2005 60
2. Greater than 85% of patients with PaO2 7.3 kPa 1987 35
2005 65
3. Greater than or equal to 95% of patients who were non-smokers 1987 90
2005 90
4. No thoracic wall deformity patients without HMV 1993 30
2005 75
Performance of LTOT
5. Greater than 90% of patients with PaO2> 8 kPa on oxygen 1987 50
2005 25
6. Greater than 90% of patients with more than 16 h a day 1987 70
2005 100
7. Greater than 50% of patients with mobile oxygen equipment 1989 60
2004 80
8. Greater than 95% of patients with reassessment of LTOT one to three
months after initiation during a COPD exacerbation
2002 0
2005 25
Concomitant treatment
9. Greater than or equal to 80% of COPD patients without
continuous oral glucocorticosteroids
1987 25
2005 50
LTOT: long-term oxygen therapy; PaO2: arterial oxygen tension; HMV: home mechanical ventilation; and COPD: chronic obstructive
pulmonary disease.
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lent quality. The importance of oxygenation during oxygen
breathing was not addressed until 2003, which may have
influenced the apparent deterioration in quality before the
time attention was paid to that indicator. We observed an
improvement in the quality indicators after they were
highlighted, and believe that continuous education and
repeated focus on results are necessary prerequisites for
a quality register, with the aim of achieving these desired
improvements.
The gradual and considerable increase in the number of
initiated LTOTs is probably a result of both the increasing
attention that has been paid to LTOT and the time course of
smoking habits in Sweden rather than a widening of the
indications for LTOT. This assumption is supported by the
decline in the percentage of patients with mild to moderate
hypoxemia. An increase in the prescription of LTOT has also
been demonstrated in Denmark, where COPD patients with
LTOT increased from 27 per 100,000 inhabitants in 1994 to
42 per 100,000 in 2000.29 The incidence of LTOT prescrip-
tions in our material varied fourfold between the counties
in 2005, which could very well reflect the regional differ-
ences in smoking related respiratory diseases, since it also
corresponds to the fourfold variations in lung cancer among
Swedish counties according to the Cancer Register of the
National Board of Health and Welfare.30
Patients with thoracic wall deformity as a cause of
chronic hypoxemia, especially those with concomitant
respiratory disorders, often receive LTOT,23 despite that the
superior survival effects of HMV in these patients and someof them actually manage well on HMV alone.21e23 We found
a substantial decrease in the prescription of LTOT without
concomitant HMV in patients with thoracic wall deformity.
In Sweden, it is recommended not to initiate LTOT in
current smokers, and adherence to this recommendation
increased during our observation period. The reason for this
recommendation is the assumed interference with the
treatment results8 and the risk of fire.18e20 Despite an
increase in mortality among current smokers,8 it is possible
that LTOT has a positive effect on survival rate in these
patients. This problem was recently addressed at the NHLBI
workshop on LTOT as an ethical issue to be included in
future studies of LTOT.31 In our patients, as many as 99%
were non-smokers at the end of the observation period, as
compared with 86% of Scottish patients and 79% of Danish
patients with LTOT, for example.9,12
In respiratory failure during exacerbation of COPD, there
is a chance of improvement of oxygenation during the
recovery.16 When initiating LTOT under these circum-
stances, the indication should, therefore, be reassessed
after 1e3 months.6 This recommendation has been
a quality indicator in our register since 2002. Despite
education in this area, its introduction on a wide scale has
been slow, probably because recovery from COPD exacer-
bations are generally not expected to last as long as three
months and because the reassessment calls for an extra
visit by the oxygen nurse. Register data show that the
proportion of LTOTs started during exacerbation in Sweden
has increased since 2002. Shorter inpatient times due to the
75% decline in the national number of hospital beds from
214 T. Gustafson et al.1987 to 2005 has probably contributed to this, and to the
diminished proportion of patients reaching adequate
oxygenation at the start of LTOT.
One of the reasons for the eight-year increase in mean
age for start of LTOT is probably the time course of smoking
in the population. Smoking has decreased since the 1970s in
Sweden. Another reason might be improvement in the
overall care of patients. The higher age at the start of LTOT
has an impact on survival rates during LTOT, which also vary
with the changes in diagnosis and sex distribution.32,33
We have studied prescribed, rather than achieved, daily
time of oxygen therapy. Compliance is a difficult issue,
which we have not addressed in any detail in this evalua-
tion.11,34,35 In our experience, the assessment of compli-
ance is too complicated to include as an indicator in
a quality register.8 When oxygen cylinder use and concen-
trator meter readings were checked in the Swedish register,
approximately 70% of patients were found to use oxygen for
a minimum of 15 h or more per day.8
The main goal of LTOT in COPD patients is to improve
survival. The effect of LTOT on survival rates depends on
the treatment time per day.1,2 Lightweight portable oxygen
equipment is important for compliance with the prescribed
hours of oxygen in patients who are active outside the
home.11 Using portable oxygen equipment may also have
a positive effect on health status.24,34,36 This assumption
was not supported by a recent study of ambulatory
oxygen,37 which found no impact on health status, as well
as fairly poor compliance. The prescription of portable
oxygen equipment to mobile patients (quality indicator 7 in
Table 1) is clearly a quality debatable indicator until new
trials elucidate the question.31 To date, our recommenda-
tion has been to try to reach a continuous adequate level of
oxygenation for the best impact on survival and health
status.
It is possible that the common prescription of oxygen for
a minimum of 16 h per day resulted in many patients not
striving to use oxygen for up to 24 h per day, and thus not
taking full advantage of their LTOT.
The survival rate among our register patients was lower
than in the NOTT and MRC studies.1,2 Compared with those
studies, patients in our evaluation were older, and patients
with very poor performance status or concomitant disease
were not excluded, as they were in the NOTT and MRC
studies. We found similar survival rate as Crockett et al.38
Their first-year survival rate was 75% in an unselected
patient group, like our patients. In Denmark, the first-year
survival rate among COPD patients with LTOT has been
found to be even lower, 55%.29 It is believed that the high
proportion of patients starting LTOT in an unstable state of
COPD has contributed to this low first year survival rate in
Danish patients. In our COPD patients, the majority started
LTOT in a stable phase of their disease. A decreasing
proportion of patients with PaO2 when breathing air of
above 7.3 kPa, and a diminished proportion of patients
reaching adequate oxygenation when breathing oxygen,
might have contributed to our absence of improvement in
survival rates. However, we believe that the most impor-
tant reason for the failure to improve survival rates was the
higher age and more compromised performance status of
patients initiated on LTOT during the latter part of the
period 1987e2004.There are no existing recommendations for levels of
excellent quality in indicators for the care of patients on
LTOT. Our choice of quality indicators was guided by pub-
lished evidence (quality indicator 2,1e3 4,21e23 5,1e3 6,1,2,8
86,16,17 and 926e28 in Table 1), and our early results (quality
indicator 1,5 38 726 in Table 1). Our suggested levels are based
on the observed county results. The latter three quality
indicators and levels for excellent quality based on our
experience are of a temporary nature and will have to be
changed according to new knowledge and guideline revi-
sions.30 This applies particularly to the access indicator
which will have to be adjusted to match the changing
epidemiology of COPD over time in the area where it is used.
In conclusion, we found improvements in eight of nine
quality indicators over 19 years of quality registration. We
propose a model for the quality assurance of LTOT, using
indicators with levels for excellent quality, based on our
estimation of current knowledge.Acknowledgements
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